Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Early Phase 1

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

Early Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06777433Phase 2Active Not Recruiting

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Role: lead

NCT05799274Phase 1Recruiting

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Role: lead

NCT07259213Phase 1Recruiting

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Role: lead

NCT07189871Phase 1Recruiting

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Role: lead

NCT07272642Phase 1Not Yet Recruiting

A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

Role: lead

NCT06305962Early Phase 1Recruiting

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Role: lead

NCT06824155Early Phase 1Recruiting

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

Role: lead

All 7 trials loaded